QL
CLDX icon

Quarry LP’s Celldex Therapeutics CLDX Stock Holding History

Quarry LP’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.16K Buy
+85
New +$2.75K ﹤0.01% 1337
2026
Q1 		– Sell
-180
Closed -$4.89K – 1570
2025
Q4 		$4.89K Buy
+180
New +$4.74K ﹤0.01% 1694

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quarry LP's CLDX Position: Q2 2026 in Review

Quarry LP opened a new position in Celldex Therapeutics (CLDX) in Q2 2026: 85 shares worth $3.16K. The stake represents ﹤0.01% of the portfolio and ranks #1337 among its holdings. This is a return to the name: Quarry LP previously reported a position in CLDX as recently as Q4 2025.

Quarry LP first reported a position in CLDX in Q4 2025 and has held it in 2 quarters since. The position peaked at $4.89K in Q4 2025. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Quarry LP held 85 shares of Celldex Therapeutics worth $3.16K as of Q2 2026.
  • Celldex Therapeutics was a new Quarry LP position in Q2 2026.
  • Celldex Therapeutics made up ﹤0.01% of Quarry LP's portfolio in Q2 2026, its #1337 holding.
  • Quarry LP first reported a position in Celldex Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Quarry LP's Celldex Therapeutics position peaked at $4.89K in Q4 2025.
  • 254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Quarry LP's 13F filing for Q2 2026, filed 14 Aug 2026.